Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model.
Collin J KrepleSusan Searles NielsenKathleen M SchochTao ShenMark ShabsovichYizhe SongBrad A RacetteTimothy M MillerPublished in: Annals of neurology (2023)
Lovastatin reduced the risk of ALS in humans, which was confirmed in an ALS mouse model by delayed symptom onset, prolonged survival, and preservation of motor neurons. Although further studies to understand the mechanism are required, lovastatin may represent a potential neuroprotective therapy for patients with ALS. These data demonstrate the utility of a combined pharmacoepidemiologic and mouse model approach. ANN NEUROL 2023.